Lori Coors, MD
Ophthalmology · Dallas, TXNPI 1427057223
Payments from drug & device makers
Across 107 payments — averaging $2059.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eyepoint US, Inc.$214K
- Alcon$4K
- Alimera Sciences, Inc.$398
- Regeneron Healthcare Solutions, Inc.$375
- Genentech USA, Inc.$337
- AbbVie$293
- plus $1K from 14 others
What the payments were for
- Consulting fees$3,43054%
- Food & beverage$2,87145%
- Education$150%
- Entertainment$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eyepoint US, Inc. | 4 | $214,023 |
| Alcon | 7 | $3,700 |
| Alimera Sciences, Inc. | 6 | $398 |
| Regeneron Healthcare Solutions, Inc. | 15 | $375 |
| Genentech USA, Inc. | 10 | $337 |
| AbbVie(2 entities) | 14 | $293 |
| Amgen | 13 | $227 |
| Bausch & Lomb Americas Inc. | 8 | $224 |
| Coherus Oncology, Inc. | 7 | $219 |
| Astellas Pharma US Inc | 7 | $186 |
| Apellis Pharmaceuticals, Inc. | 3 | $91 |
| Carl Zeiss Meditec USA, Inc. | 3 | $65 |
| Sandoz | 2 | $60 |
| Harrow Eye, LLC | 2 | $44 |
| Optos, Inc. | 1 | $30 |
| Novartis | 1 | $21 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $19 |
| Dutch Ophthalmic, USA | 1 | $15 |
| Carl Zeiss Meditec, Inc. | 1 | $12 |
| Travere Therapeutics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Constellation$3,585
- VABYSMO$150
- YUTIQ$128
- Iluvien$128
- XIPERE$101
How this compares
$220,351 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 303 | $9,677 |
| Brimonidine Tartrate | 52 | $3,124 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 26 | $2,284 |
| Ofloxacin | 221 | $2,079 |
| Difluprednate | 13 | $1,998 |
| Latanoprost | 139 | $1,169 |
| Timolol Maleate | 28 | $215 |
| ErythromycinErythromycin Base | 18 | $209 |
| Tramadol Hcl | 101 | $125 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 19 | $108 |
| Tobramycin | 13 | $58 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Dallas
- Ashkan AbbeyDallas$5.7M
- Karl CsakyDallas$4.9M
- Jeffrey WhitmanDallas$1.7M
- Oluwatosin SmithDallas$1.7M
- Davinder GroverDallas$1.3M
- Robert WangDallas$594K
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
- Chirag JhaveriAustin$9.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.